Company
Organisation
Enzymatica has 18 employees. The headquarters are located at Ideon Science Village in Lund, Sweden. In addition, Enzymatica has an office and enzyme production in Reykjavik, Iceland.
Board of Directors
IThe Board of Directors consists of six members who are elected for one year by the Annual General Meeting. According to the Articles of Association, the Board of Directors shall consist of at least three and a maximum of ten members with a maximum of ten deputies. The Board of Directors elects its officers at a meeting held immediately after the Annual General Meeting.
Holdings in Enzymatica, October 2, 2024
Born 1962.
Chairman of the Board of Thule Group AB (publ), ifoodbag AB and 5653 Sweden AB. Board member of APAC . Bengt was previously CEO of Cloetta AB, Leaf International B.V. and V&S AB
Education: B.Sc. and MBA, University of California, Berkeley
Independent of the company, company management and major shareholders.
Holdings in Enzymatica: 5,108,207 shares (own holding and through 5653 Sweden AB).
Born 1955.
Chairman of the Board of Lomond Invest AB, Abanico Invest AB and Andersson & Co AB, Board member of Hills Golf AB. Mats was previously CEO of Lomond Industrier AB and business area manager and Executive Vice President of LICare AB (publ).
Education: BSc. International Business from Lund University.
Dependent in relation to major shareholders. Independent in relation to the company and company management.
Holdings in Enzymatica: 58,736,203 shares (through Abanico Invest AB).
Born 1973.
Chairman of the Board for Better Business World Wide,Board member for Volati AB (publ), VBG Group AB (publ), Seafire AB, Atteviks Bil AB and Optinova Group (Ab) Finland. Has run the consultancy at Nicolin Consulting AB since 2011, with a focus on business development . She was previously business area manager and head consultant at PlantVision.
Education: M.Sc. Eng. Molecular biotechnology from Uppsala University. eMBA Stockholm University and “International Directors Programme (IDP-c)", Insead.
Independent of the company, company management and major shareholders.
Holdings in Enzymatica: 147,777 shares.
Born 1968.
CEO and director of STRAX AB (publ.) Chairman and co-founder of Verna hf. Extensive experience in international business and contract law. Previous positions include Chairman of Zymetech ehf. and Alternate Board member of MP Bank hf. (now Kvika bank).
Education: LL.M, MBA and Cand.Jur.
Independent of the company, company management and major shareholders.
Holdings in Enzymatica: 5,108,207 shares (through Fortus hf and Ultima Thule LLC).
Born 1967.
Chairman at AX VII Holding AB. Board member at Thule Group AB, Nordic Paper Holding AB, Profoto Holding AB, Infrea AB, and Indecap Holding AB.
Education: Degree of Master of Science in Business and Economics from Stockholm School of Economics.
Independent of the company, company management and major shareholders.
Holdings in Enzymatica: 1,943,944 shares.
Born 1982.
CEO Genagon Therapeutics, Stockholm.
Board member of AFradiolog AB, previous experience from pre-clinical development of gene therapy and CAR-T cell treatments and co-founder of Bioflow systems. Moa has a vast experience in coaching entrepreneurs and startups in Sweden and Europe
Education: Doctor of Medicine, Gene and immunotherapy, Uppsala University.
Independent of the company, company management and major shareholders.
Holdings in Enzymatica: 0 shares.
Board members’ shareholdings as of December 31, 2023, attendance record for 2023, and respective independence to owners and the Company, respectively
| Name | Number of shares | Attendance board | Independence to owners and the Company, respectively |
|---|---|---|---|
| Bengt Baron, chairman (since December 19, 2016) | 3,507,859 | 12/12 | Yes/Yes |
| Mats Andersson | 36,398,195 | 12/12 | No/Yes |
| Gudmundur Palmason | 6,545,837 | 12/12 | Yes/Yes |
| Moa Fransson | 0 | 12/12 | Yes/Yes |
| Helene Willberg | 228,753 | 12/12 | Yes/Yes |
| Louise Nicolin | 100,000 | 11/12 | Yes/Yes |
Management
The CEO is appointed by the Board of Directors and leads the Company in accordance with the guidelines and instructions adopted by the Board. The CEO appoints a Management Group.
Holdings in Enzymatica as of October 2, 2024
Born 1961.
Claus Egstrand has previously held positions as Head of Europe for MSD Consumer Care at the pharmaceutical company Merck & Co, as well as Vice President, General Manager Medsurg Europe for the medical technologies firm Stryker Corporation.
Claus has served as Senior Vice President Consumer Healthcare for Latin America, Africa, Asia, Japan and Australia at the pharmaceutical company Pfizer, Vice President and head of global marketing for the smoking cessation product Nicorette at the pharmaceutical company Pharmacia, as well as CEO of Johnson&Johnson/Merck Pharmaceuticals operations in France. His most recent position was Group President, International at Hologic Corp.
Education: MBA, Business School of Copenhagen
Holdings in Enzymatica: 2,668,275 shares, 250,000 personnel options, 800,000 warrants.
Born 1969.
Therese has extensive experience as CFO. Most recently, Therese was CFO and deputy CEO of the Procurator Group, one of the leading Nordic wholesalers in protective clothing, sanitary goods and office materials.
Before that, Therese worked at MTG (including CDON and TV Shop) and Bravida Syd. In addition to responsibility for financial issues, Therese has been responsible for HR, legal and strategic IT issues.
Education: M.Sc. Econ Lund University and B.A. in pedagogics/human resources.
Holdings in Enzymatica: 425,000 shares and 100,000 warrants.
Born 1967.
Ann-Christine has over 25 years of experience from various expert and management positions within regulatory affairs in the medical device industry, including companies such as Siemens, Medtronic, EuroDiagnostica and also start-up companies such as BoneSupport. Her experience includes all phases of global regulatory strategies, including executing strategies for market access for medical devices within all classes.
Education: Master of Science in Material Science, Royal Institute of Technology, Stockholm.
Holdings in Enzymatica: 0 shares and 250,000 warrants.
Born 1972.
Charlotte Andersson has long experience from the life science industry, most recently from BioInvent where she was the Senior Quality Assurance Advisor. Charlotte Andersson has substantial experience of quality assurance from the medtech industry, IVD business (In vitro Dignostics), and the pharmaceutical and biotech area. She has held different positions within quality management, including ISO 13485, ISO 17025, GMP (Good Manufacturing Practice). At BioInvent, she was the Senior Quality Assurance Advisor and has also held different positions within the quality field at companies like Wieslab, EuroDiagnostica, Orifice Medical and NovoZymes Biopharma Sweden.
Education: M.Sc. Chemical Engineering, Lund Institute of Technology, Lund University.
Ph.D. Pure and Applied Biochemistry, Lund Institute of Technology, Lund University.
Holdings in Enzymatica: 0 shares and 100,000 warrants.
Born 1981.
Chris Czyrko joined Enzymatica from Venture Life Group where he was employed as Head of International Alliance Management, overseeing relationships with over 40 partners and 12 brands. Prior to Venture Life Group, Chris worked as International Commercial Manager and Supply Chain Liaison at BBI Healthcare, operating as part of the management team overseeing the sale of the business. From 2017 to 2021 Chris worked at BBI, managing distribution relationships with international partners in Europe, North America and further afield, as well as managing CMO partners for medical devices, cosmetics and food supplements.
Education: CIM Professional Post Graduate Diploma in Marketing, BA (Hons) International Marketing Management, University of Bournemouth.
Holdings in Enzymatica: 37,000 shares.
Born 1966.
Claes has extensive experience from leading positions for production and supply chain operations within the pharmaceutical industry, including nine years within AstraZeneca. He most recently comes from a role as the Director Operations Sweden within the Venture Life Group, which develops, manufactures and distributes OTC products in personal care. Claes has many years of experience from developing numerous production and supply chain operations by expanding manufacturing volumes, increasing productivity and ensuring the quality requirements for new certificates and registrations of pharmaceutical and medical technology products.
Education: Natural science studies at Gothenburg University.
Holdings in Enzymatica: 60,200 shares and 100,000 warrants.